Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Leap 1030
- Development stage
- Preclinical
- Lead developer
- Ability Biologics
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Leap 1030 is a preclinical-stage, contextually-gated antibody being developed by Ability Biologics for the treatment of solid tumors. Developed using the proprietary AbiLeap™ generative AI platform, Leap 1030 is designed as a pH-sensing T-cell engager. This logic-gated approach allows the therapeutic to remain inactive in healthy tissues but become selectively active within the acidic microenvironment characteristic of solid tumors. By focusing antibody activity to the tumor site, Leap 1030 aims to enhance therapeutic efficacy while minimizing systemic toxicities often associated with T-cell engaging therapies.
Beyond the preview
Go deeper on Leap 1030.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Leap 1030.